<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897244</url>
  </required_header>
  <id_info>
    <org_study_id>201812129MINC</org_study_id>
    <nct_id>NCT03897244</nct_id>
  </id_info>
  <brief_title>Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication</brief_title>
  <official_title>Efficacies of High-dose Dual Therapy With or Without Bismuth Versus Amoxicillin-metronidazole Bismuth Quadruple Therapy for First-line Helicobacter Pylori Eradication - A Prospective, Randomized, Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to know, three is few large-scale, randomized study prospectively and simultaneously
      comparing the efficacy, adverse effects and patient compliance of high-dose dual therapy
      (HDDT) with or without bismuth versus amoxicillin-metronidazole bismuth quadruple therapy
      (AM-BQT) as first-line regimens for H. pylori eradication.

      The aims of this study are:

        1. to compare the efficacy of HDDT with or without bismuth and AM-BQT as first-line
           regimens for H. pylori eradication;

        2. to compare the patient adherence and adverse effects of these treatment regimens;

        3. to investigate factors that may influence H. pylori eradication by these treatment
           regimens;

        4. to identify the effect of H. pylori eradication on the evolution of ecosystem of
           microbiota, and inflammatory parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective multicenter randomized comparative study will be conducted at the National
      Taiwan University Hospital(NTUH), NTUH Bei-Hu Branch, NTUH Hsin-Chu Branch, Buddhist Tzu Chi
      General Hospital, and Mennonite Christian Hospital in Hua-Lien City. Patients, aged &gt;= 20,
      having H. pylori-positive chronic gastritis with/without peptic ulcers (duodenal or gastric
      ulcers) will be recruited. All undergo endoscopy with biopsy for rapid urease test,
      histology, and bacterial culture before treatment. If the patients did not receive anti-H.
      pylori therapy previously, these patients will be invited to enter this study for evaluating
      the efficacy of these 1st-line regimens.

      A computed generated random numbers sequence will be blocked into three subgroups, say A, B,
      and C. After giving written informed consent, each patient will be randomly allocated, to one
      of three treatment groups:

      group A - HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days);

      group B - Bis-HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate
      bismuthate 300 mg qid, for 14 days);

      group C - AM-BQT (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid +
      amoxicillin 1000 mg bid + metronidazole 500 mg tid , for 14 days);

      All patients will be asked to complete a questionnaire and to record symptoms, drug
      consumption, and diet content daily during the treatment period. Post-treatment, the patients
      will be followed up at the Outpatients Clinic to investigate patient adherence and adverse
      effects of treatment. Four to eight weeks after termination of treatment, H. pylori infection
      status will be examined by the C13-urea breath test (UBT). The CYP2C19 genotype of each
      participant will be analyzed by the polymerase chain reaction-based restriction fragment
      length polymorphism (PCR-RFLP) method. A part of participants, at least 30 cases in each
      group, will be invited to join a follow-up program for one year for evaluating the changes or
      evolution of gut microbiota composition, metabolic product, parameters of inflammation and
      immune response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to compare the eradication rate of HDDT with or without bismuth and AM-BQT as first-line regimens for H. pylori eradication.</measure>
    <time_frame>3.5 years</time_frame>
    <description>The eradication rates (efficacy) of these regimens will be evaluated by the results of C13-urea breath test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to compare the patient adherence and frequency of adverse effects of these treatment regimens.</measure>
    <time_frame>3.5 years</time_frame>
    <description>The frequency of adverse events will be evaluated by the number of participant with adverse events and patient adherence will be evaluated by counting unused medication after the treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">702</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>High-dose dual therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group A - HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bismuth High-dose dual therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group B - Bis-HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin-Metronidazole Bismuth quadruple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group C - AM-BQT (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose dual therapy (rabeprazole, amoxicillin)</intervention_name>
    <description>High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)</description>
    <arm_group_label>High-dose dual therapy</arm_group_label>
    <other_name>Proton pump inhibitor, Rabeprazole, Pariet®</other_name>
    <other_name>Antibiotics, Amoxicillin ,Amoxicillin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)</intervention_name>
    <description>Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)</description>
    <arm_group_label>Bismuth High-dose dual therapy</arm_group_label>
    <other_name>Proton pump inhibitor, Rabeprazole, Pariet®</other_name>
    <other_name>Antibiotics, Amoxicillin ,Amoxicillin®</other_name>
    <other_name>Colloidal Bismuth, Tripotassium dicitrate bismuthate, KCB®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-Metronidazole Bismuth quadruple therapy</intervention_name>
    <description>Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)</description>
    <arm_group_label>Amoxicillin-Metronidazole Bismuth quadruple therapy</arm_group_label>
    <other_name>Proton pump inhibitor, Rabeprazole, Pariet®</other_name>
    <other_name>Antibiotics, Amoxicillin, Amoxicillin®</other_name>
    <other_name>Antibiotics, Metronidazole, Flagyl®</other_name>
    <other_name>Colloidal Bismuth, Tripotassium dicitrate bismuthate, KCB®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria: participants having H. pylori related chronic gastritis with/without
        peptic ulcers who are aged greater than 20 years old and are willing to received first-line
        eradication therapy.

        Exclusion criteria:

          1. pregnant or nursing woman;

          2. serious concomitant illness and malignant tumor of any kind;

          3. history of hypersensitivity to test drugs；

          4. serious bleeding during the course of this ulcer;

          5. previous gastric surgery;

          6. receiving bismuth salts, proton pump inhibitors (PPIs), or antibiotics in the previous
             month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyh-Chin Yang, M.D.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Chin Yang, M.D.Ph.D.</last_name>
    <phone>02-23123456</phone>
    <phone_ext>65055</phone_ext>
    <email>jcyang47@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chien-Chih Tung, M.D.</last_name>
    <phone>02-23123456</phone>
    <phone_ext>66518</phone_ext>
    <email>cnicemike@yahoo.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh-Chin Yang, M.D.Ph.D.</last_name>
      <phone>02-23123456</phone>
      <phone_ext>65055</phone_ext>
      <email>jcyang47@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>high dose dual therapy</keyword>
  <keyword>bismuth high-dose dual therapy</keyword>
  <keyword>bismuth quadruple therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

